Selling Messages Flashcards
Control more than one measure of uncontrolled asthma…
(3 measures)
Exacerbation reduction - up to 81% significant reduction in annualized rate of severe exacerbation thru week 24
Lung function improvement- rapid FEV (forced expiratory volume) at week 2 and sustained thru week 52
OCS reduction / elimination - 86% of patients reduced or eliminated their OCS at week 24
Treat more than one asthma patient type… specifically indicated for ______ Dependent _______ Patients and for moderate to ________ Asthma patients with ___________ phenotype
OCS
ASTHMA
SEVERE
EOSINOPHILLIC
Targets more than one ___ of type __________ By specifically __________ IL_ and IL_ ___________
Source
Type 2 inflammation
Inhibiting IL4 and IL13
Signalling
Markers of type 2 inflammation
(Proven data in indicated patients with >1 of the following)
EOS > 150 cells / microliter
igE > 30 IU / mL
FeNO > 20 ppb
(Fractional exhaled nitric oxide - measures airway inflammation)
Prescribed to ______ patients since ________ in patients aged ____ with moderate to severe asthma
116k
2018
12+
MOA
Only Dupixent targets both ____ and ____ ___________, two of the key ________ Of local and ______ type __ ___________
IL4 and IL13
Signalling
Drivers
Systemic
Type 2 inflammation
Patients on medium to high OCS dose + one or more controller
% and mL improvement
~72% of the total improvement at week 2…. 470mL improvement at week 52 (placebo 170mL)
The higher the EOS, the better the improvement (QUEST) — lung function improvement in patients with elevated EOS
EOS > 150 cells - 390ml improvement (150mL diff)
EOS > 300 - 480ml (250 diff)
EOS > 500 - 570ml (300 diff)
Patients on medium to high ICS dose + one or more controller
QUEST primary end point
Up to ____ % reduction in _________ through week _______
81%
Severe exacerbations thru week 24
Patients on medium to high ICS dose + one or more controller
QUEST primary end point
____ % of patients did not have an _______ requiring ________ or ED visit thru weeks ___ to ___.
97%
Exacerbation
Hospitalization
48 to 96 weeks
Patients on medium ICS dose + one or more controller
QUEST primary end point
Severe exacerbations thru W52
____ % reduction in severe exacerbations thru week 52
___ severe exacerbations thru week 96
71%
Zero
Patients on medium ICS dose + one or more controller
Rapid lung function improvement patients can feel as early as week 2
__% of the total improvement at week __
___ mL improvement at week ____
Up to ___ years of _____ relief
75%
510mL
3 years of breathing relief
Side effects of maintenance OCS
Short term - SPF
Long term - OCD
Short term
Sleep disturbance
Increases risk of fracture
Pneumonia
Long term
Obesity
Diabetes
Cataracts
Dupixent is the only FDA-approved biological indicated for ___________ patients.
OCS-dependent asthma
79% of patients from _______ eliminated their OCS dose for up to E years
VENTURE
Dupixent improved asthma control in patients 12+ years as measured by ACQ-5
Up to __% Improved asthma ______
With Dupixent ___mg Q2W + SOC vs ___% With placebo + SOC
75%
Asthma control
200
67%
Dupixent improved QOL for 12+
__% vs __%
71% vs 55%
Most common side effects…
Injection site reactions
Oropharyngeal pain (pharynx)
Eosinophilia (high)
Dupixent is a _____-recognized treatment option for children with asthma aged __ to ___ and has a demonstrated ____ profile
GINA - Global initiative for asthma
6-11
Safety
Dupixent significantly reduce severe exacerbations in children, age 6 to 11 years old
Annualized rate of severe exacerbations thru week 52 in eosinophilic phenotype (VOYAGE, primary endpoint)
EOS > 150 cells or FENO > 20ppb = ___ % reduction
EOS > 300 = ___ % reduction
59% reduction
65% reduction
Dupixent sustained lung function, improvement in children, aged 6 to 11 years
_x improvement was seen with D at W12 in percent predicted pre-bronchialator FEV vs placebo
_x improvement at week 52
2x
3x
Dupixent reduced SCS use and improved asthma, control in children, aged 6 to 11 years
SCS reduction thru week 52
___% for EOS150, Feno20
___% for EOS300
59%
66%
Long term SCS use may have significant side effects in children
LIGB
Lower height in adulthood
Increased susceptibility to infection
Gastrointestinal and cardiovascular complications
Behavioral changes
SCS
Systemic corticosteroids
Prednisone
